CN101820904A - 引起针对大流行性流感病毒的免疫应答的方法 - Google Patents

引起针对大流行性流感病毒的免疫应答的方法 Download PDF

Info

Publication number
CN101820904A
CN101820904A CN200880111106A CN200880111106A CN101820904A CN 101820904 A CN101820904 A CN 101820904A CN 200880111106 A CN200880111106 A CN 200880111106A CN 200880111106 A CN200880111106 A CN 200880111106A CN 101820904 A CN101820904 A CN 101820904A
Authority
CN
China
Prior art keywords
influenza
immunogen
subtype
iscomatrix
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880111106A
Other languages
English (en)
Chinese (zh)
Inventor
M·皮尔斯
S·罗克曼
D·瑞安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Ltd filed Critical CSL Ltd
Publication of CN101820904A publication Critical patent/CN101820904A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200880111106A 2007-10-12 2008-10-09 引起针对大流行性流感病毒的免疫应答的方法 Pending CN101820904A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97957207P 2007-10-12 2007-10-12
US60/979,572 2007-10-12
PCT/AU2008/001500 WO2009046497A1 (en) 2007-10-12 2008-10-09 Method of eliciting an immune response against pandemic influenza virus

Publications (1)

Publication Number Publication Date
CN101820904A true CN101820904A (zh) 2010-09-01

Family

ID=40548886

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880111106A Pending CN101820904A (zh) 2007-10-12 2008-10-09 引起针对大流行性流感病毒的免疫应答的方法

Country Status (10)

Country Link
US (1) US8999353B2 (https=)
EP (1) EP2195019A4 (https=)
JP (1) JP2011500514A (https=)
KR (1) KR20100082825A (https=)
CN (1) CN101820904A (https=)
AU (1) AU2008310312B2 (https=)
CA (1) CA2700937C (https=)
NZ (1) NZ583377A (https=)
SG (1) SG185294A1 (https=)
WO (1) WO2009046497A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112469436A (zh) * 2018-03-19 2021-03-09 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2595653B1 (en) 2010-07-23 2017-06-28 Novavax AB Influenza vaccine
US9524531B2 (en) * 2011-05-09 2016-12-20 Microsoft Technology Licensing, Llc Extensibility features for electronic communications
DK2750683T4 (da) 2011-10-03 2021-04-12 Croda Int Plc Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323733A1 (en) 1998-04-13 1999-10-21 Michael B. Brenner Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof
ES2572834T3 (es) * 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
NZ518401A (en) * 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
NZ520976A (en) * 1999-11-19 2005-01-28 Csl Ltd Vaccine compositions
AU2001251316A1 (en) 2000-04-04 2001-10-15 Antigenics Inc. Isolated and purified nonpeptide antigens from mycobacterium tuberculosis
US20040081654A1 (en) 2000-06-16 2004-04-29 Schryvers Anthony B Use of plant oil-bodies in vaccine delivery systems
GB0021757D0 (en) 2000-09-04 2000-10-18 Colaco Camilo Vaccine against microbial pathogens
US20060210555A1 (en) * 2001-12-21 2006-09-21 Antigenics, Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
US20030190333A1 (en) * 2002-02-04 2003-10-09 Corixa Corporation Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
GB0401239D0 (en) 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions
AU2005244128B2 (en) 2004-05-07 2009-06-25 President And Fellows Of Harvard College Pulmonary malarial vaccine
US20060287263A1 (en) * 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
US20070190072A1 (en) * 2004-09-30 2007-08-16 Csl Limited Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus adjuvant
AR054020A1 (es) * 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
CA2662164A1 (en) * 2006-09-01 2008-03-06 Stirling John Edwards Method of eliciting or inducing an immune response

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112469436A (zh) * 2018-03-19 2021-03-09 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗

Also Published As

Publication number Publication date
KR20100082825A (ko) 2010-07-20
AU2008310312B2 (en) 2013-12-19
JP2011500514A (ja) 2011-01-06
CA2700937A1 (en) 2009-04-16
US8999353B2 (en) 2015-04-07
CA2700937C (en) 2017-05-09
EP2195019A4 (en) 2012-02-15
NZ583377A (en) 2013-11-29
WO2009046497A1 (en) 2009-04-16
US20100291146A1 (en) 2010-11-18
EP2195019A1 (en) 2010-06-16
SG185294A1 (en) 2012-11-29
AU2008310312A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
US9730999B2 (en) Adjuvanted influenza virus compositions
US10793834B2 (en) Live-attenuated virus and methods of production and use
JP5809560B2 (ja) インフルエンザに対して使用するためのワクチン組成物
JP6185548B2 (ja) インフルエンザワクチンの製造方法
US20120207785A1 (en) Process for preparing an influenza seed virus for vaccine manufacture
EP2015774A1 (en) Influenza virus vaccine
Wu et al. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine
Kim et al. Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection
US8999353B2 (en) Method of eliciting an immune response against pandemic influenza virus
US11369675B2 (en) Broadly protective inactivated influenza virus vaccine
KR20120131725A (ko) 고병원성 조류인플루엔자 ａ ｈ５ｎ１ 바이러스 유사입자 및 이를 이용한 가금용 백신
Gruber The role of live influenza vaccines in children
CN101808659A (zh) 灭活的流感疫苗
TW200844236A (en) Multivalent avian influenza vaccines and methods
US20240335522A1 (en) Multivalent pan-influenza vaccine
Oxford et al. Influenza vaccines have a short but illustrious history of dedicated science enabling the rapid global production of A/swine (H1N1) vaccine in the current pandemic
CN101405027B (zh) 基于病毒颗粒的鼻内流感疫苗
Rudometov et al. DNA Vaccine Encoding a Modified Hemagglutinin of Influenza A/H5N8 Virus Protects Mice from Infection with a Lethal Dose of Influenza A/H5N1 Virus
CA2583555C (en) Influenza vaccine
Treanor et al. New approaches to influenza vaccine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100901